MenopauseNCT05299983

MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

A study testing MyMenoPlan in people with Menopause and Premenopause, run by University of California, San Diego at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 40 to 60 years, women onlyHealthy volunteers can take part
Conditions the study is for: Menopause, Premenopause, Postmenopause
What is being tested?: MyMenoPlan
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 410 participants
Where: 1 siteUnited States
Study dates: 15 Jan 2022to 31 Mar 2022
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 60 years
Women only
Healthy volunteers accepted
Adult

Who may be able to join

As stated above

Who cannot join

Trial locations and contacts

1 site in 1 country.

United States1 site

UC San Diego
La Jolla, California, 92037

Other trials in United States

About this study

Official title: MsFLASH: Living a Healthy Menopause, Aim 2 Randomized Controlled Trial of MyMenoPlan

As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

Read the detailed description

The purpose of this research study is to:

Investigate how women randomly assigned to visit MyMenoPlan use the website (time spent on website, treatment and symptom page views, use of interactive tools, and use of the MyMenoPlan tool).
Compare the ratings of women randomly assigned to MyMenoPlan to those randomly assigned to other menopause websites for perceived quality of information, readability, self-efficacy, and credibility of these online menopause resources.

Conditions: Menopause, Premenopause, Postmenopause
Being tested: MyMenoPlan, Control
Keywords: Computer-Assisted Decision Making, Internet-Based Intervention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

MyMenoPlanOther
Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
ControlOther
Participants are asked to spend at least 20 minutes on at least one of the following websites:
1. North American Menopause Society: https://www.menopause.org/for-women
2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause
3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause

Study groups in NCT05299983
Study group	Role	What they receive
MyMenoPlan	Experimental	Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them. Receives: Other: MyMenoPlan
Control	Active comparator	Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice: 1. North American Menopause Society: https://www.menopause.org/for-women 2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause 3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause Receives: Other: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

Perceived Quality of Information
This 7-item, 5-point Likert scale (1- Strongly disagree to 5 - Strongly agree) is adapted from the Post-Study System Usability Questionnaire (PSSUQ) in Lewis (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (perceived quality of information).
Items:
1. Reading the information made me feel in more control of my perimenopause/menopause.
2. The information on the website(s) was helpful to me.
3. I found the information I was looking for.
4. The information answered my questions about perimenopause/menopause.
5. I liked the website (s).
6. I would have liked more in-depth information. (reverse-coded)
7. The website(s) were fairly comprehensive about perimenopause /menopause.
Measured: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
Readability
This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree)scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (readability).
Items:
1. The information I read was clear.
2. The information I read was easy for me to understand.
Measured: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
Self-Efficacy for Managing Menopause Symptoms
This is a newly developed Likert scale (1- Strongly disagree to 5 - Strongly agree) for assessing participants' beliefs in their own abilities in managing menopausal symptoms. The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (self-efficacy).
Items:
1. If I want to, I am certain I could figure out the treatments or coping strategies that would work best for me.
2. I feel I could treat or cope with my symptoms of perimenopause/menopause if I want to.
Measured: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
Credibility
This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree) scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (credibility).
Items:
1. The information is credible.
2. The information is trustworthy.
Measured: Each survey question is answered after spending at least 20 minutes on the assigned website(s)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Jan 202231 Mar 2022

First posted29 Mar 2022
Study start15 Jan 2022
Primary completion31 Mar 2022
Study completion31 Mar 2022

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for MenopauseStudies of the same condition, open and under way.
More trials run by University of California, San DiegoThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Health services research
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 410 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05299983
Sponsor's protocol ID: 140604
Status last verified: Mar 2025
First submitted: 1 Mar 2022
Last updated: 27 Mar 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Publications

Snyder LB, Newton KM, Ng HX, Reed SD, Guthrie KA, Zambrano V, LaCroix AZ. Positive impact of a menopause website - MyMenoplan.org - on treatment intentions, knowledge, and decision making: A randomized controlled trial. Maturitas. 2025 Aug;199:108630. doi: 10.1016/j.maturitas.2025.108630. Epub 2025 Jun 5.
PubMed 40505527

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruiting
The Role of Diet Quality in Sleep Among Women in Postmenopause
Post Menopausal Women
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer

All Menopause trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: MsFLASH: Living a Healthy Menopause, Aim 2 Randomized Controlled Trial of MyMenoPlan
ClinicalTrials.gov ID: NCT05299983
Acronym / sponsor ID: 140604
Conditions: Menopause, Premenopause, Postmenopause
Keywords: Computer-Assisted Decision Making, Internet-Based Intervention
Study type: Interventional
Recruitment status: Completed
Enrolment: 410 participants (actual)
Lead sponsor: University of California, San DiegoUniversity, hospital or other
Study start: 15 Jan 2022 (actual)
Primary completion: 31 Mar 2022 (actual)
Study completion: 31 Mar 2022 (actual)
First posted: 29 Mar 2022 (actual)
Results: Posted 27 Mar 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

The purpose of this research study is to:

Investigate how women randomly assigned to visit MyMenoPlan use the website (time spent on website, treatment and symptom page views, use of interactive tools, and use of the MyMenoPlan tool).
Compare the ratings of women randomly assigned to MyMenoPlan to those randomly assigned to other menopause websites for perceived quality of information, readability, self-efficacy, and credibility of these online menopause resources.

Study design

Primary purpose: Health services research
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 2

Arm	Type	Receives
MyMenoPlan	Experimental	Other: MyMenoPlanParticipants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
Control	Active comparator	Other: ControlParticipants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice: 1. North American Menopause Society: https://www.menopause.org/for-women 2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause 3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause

Who may qualify

Ages: 40 to 60 years
Sex: Female only
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (1 listed)

As stated above

Key exclusion criteria (1 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
MyMenoPlanParticipants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.	Other	MyMenoPlan
ControlParticipants are asked to spend at least 20 minutes on at least one of the following websites: 1. North American Menopause Society: https://www.menopause.org/for-women 2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause 3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause	Other	Control

Primary outcome

Perceived Quality of Information
Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
This 7-item, 5-point Likert scale (1- Strongly disagree to 5 - Strongly agree) is adapted from the Post-Study System Usability Questionnaire (PSSUQ) in Lewis (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (perceived quality of information). Items: 1. Reading the information made me feel in more control of my perimenopause/menopause. 2. The information on the website(s) was helpful to me. 3. I found the information I was looking for. 4. The information answered my questions about perimenopause/menopause. 5. I liked the website (s). 6. I would have liked more in-depth information. (reverse-coded) 7. The website(s) were fairly comprehensive about perimenopause /menopause.
Readability
Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree)scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (readability). Items: 1. The information I read was clear. 2. The information I read was easy for me to understand.
Self-Efficacy for Managing Menopause Symptoms
Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
This is a newly developed Likert scale (1- Strongly disagree to 5 - Strongly agree) for assessing participants' beliefs in their own abilities in managing menopausal symptoms. The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (self-efficacy). Items: 1. If I want to, I am certain I could figure out the treatments or coping strategies that would work best for me. 2. I feel I could treat or cope with my symptoms of perimenopause/menopause if I want to.
Credibility
Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s)
This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree) scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (credibility). Items: 1. The information is credible. 2. The information is trustworthy.

Results and safety

Results posted to the registry on 27 Mar 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
MyMenoPlan	200	200
Control	210	210

Primary outcome: Perceived Quality of Information

Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Mean (Standard Deviation). Unit: score on a scale

Measure	MyMenoPlan n = 200	Control n = 210
Value	4.1 (0.59)	3.7 (0.73)

MyMenoPlan vs Control: p <.001, Chi-squared

Primary outcome: Readability

Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Mean (Standard Deviation). Unit: score on a scale

Measure	MyMenoPlan n = 200	Control n = 210
Value	4.6 (0.52)	4.4 (0.67)

MyMenoPlan vs Control: p = 0.02, Chi-squared

Primary outcome: Self-Efficacy for Managing Menopause Symptoms

Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Mean (Standard Deviation). Unit: score on a scale

Measure	MyMenoPlan n = 200	Control n = 210
Value	4.0 (0.66)	3.9 (0.71)

MyMenoPlan vs Control: p = 0.22, Chi-squared

Primary outcome: Credibility

Time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s). Mean (Standard Deviation). Unit: score on a scale

Measure	MyMenoPlan n = 200	Control n = 210
Value	4.3 (0.66)	4.4 (0.65)

MyMenoPlan vs Control: p = 0.45, Chi-squared

Adverse events

Time frame: Participants were asked to spend at least 20 minutes reviewing websites.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
MyMenoPlan	0 of 200 (0%)	0 of 200 (0%)	0 of 200
Control	0 of 210 (0%)	0 of 210 (0%)	0 of 210

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40505527Snyder LB, Newton KM, Ng HX, Reed SD, Guthrie KA, Zambrano V, LaCroix AZ. Positive impact of a menopause website - MyMenoplan.org - on treatment intentions, knowledge, and decision making: A randomized controlled trial. Maturitas. 2025 Aug;199:108630. doi: 10.1016/j.maturitas.2025.108630. Epub 2025 Jun 5.

Related trials for Menopause

Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruiting
The Role of Diet Quality in Sleep Among Women in Postmenopause
Post Menopausal Women
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Andrea Z. LaCroix, PhD principal investigator

University of California, San Diego

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing MyMenoPlan in people with Menopause and Premenopause, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Mar 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Perceived Quality of Information (time frame: Each survey question is answered after spending at least 20 minutes on the assigned website(s)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05299983, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2025.